

# Hemorif<sup>®</sup>

Diosmin BP 450 mg & Hesperidin INN 50 mg

## COMPOSITION

Each film coated tablet contains micronised Diosmin BP 450 mg and Hesperidin INN 50 mg.

## PHARMACOLOGY

**Hemorif<sup>®</sup>** is a phlebotonic drug and a vascular protecting agent. It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus **Hemorif<sup>®</sup>** decreases venous capacitance, venous distensibility, and venous emptying time.

**Hemorif<sup>®</sup>** protects the microcirculation by fighting the microcirculation damaging process; It combats venous inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandin. Thus **Hemorif<sup>®</sup>** normalizes capillary permeability and strengthens capillary resistance.

**Hemorif<sup>®</sup>** acts on the lymphatic system, It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure.

## INDICATION

Acute hemorrhoidal attacks.  
Chronic hemorrhoidal disease.  
Organic and functional chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs, pain, nocturnal cramps.

## DOSAGE & ADMINISTRATION

Tablet should be taken at meal times.  
Acute hemorrhoidal attacks: 3 tablets twice daily for the first

4 days, then 2 tablets twice daily for three days and if required 1 tablet twice daily as maintenance dosage.

Chronic hemorrhoids: 1 tablet twice daily.

Chronic venous insufficiency: 1 tablet twice daily initially for seven

days. Duration may be increased depending on severity.

## CONTRAINDICATION & PRECAUTION

Proper data on contraindication is not available. If the hemorrhoidal symptoms do not disappear within 15 days, patient should ask doctor for advice.

## SIDE EFFECT

Some cases of routine gastric disorders and neurovegetative disorders (feeling of discomfort) have been reported. In this cases discontinuation of treatment is not required.

## DRUG INTERACTION

Proper data is not available.

## USE IN PREGNANCY & LACTATION

Experimental studies in animal have not demonstrated any teratogenic effects and no harmful effect have been reported in women to date. Breast feeding is not recommended during treatment.

## STORAGE

Protected from light & moisture. Store below 30° C. Keep all medicines out of reach of children.

## HOW SUPPLIED

**Hemorif<sup>®</sup>** tablet : Box containing 30's tablet in blister pack.

Manufactured by



**SQUARE**  
**PHARMACEUTICALS LTD.**  
**BANGLADESH**